A detailed history of Lvm Capital Management LTD transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Lvm Capital Management LTD holds 13,550 shares of BMY stock, worth $770,182. This represents 0.08% of its overall portfolio holdings.

Number of Shares
13,550
Previous 13,550 -0.0%
Holding current value
$770,182
Previous $562,000 24.73%
% of portfolio
0.08%
Previous 0.06%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

Apr 15, 2024

SELL
$47.98 - $54.4 $7,196 - $8,160
-150 Reduced 1.09%
13,550 $734,000
Q4 2023

Jan 12, 2024

SELL
$48.48 - $57.85 $9,696 - $11,570
-200 Reduced 1.44%
13,700 $702,000
Q3 2023

Oct 10, 2023

SELL
$57.89 - $64.73 $28,945 - $32,365
-500 Reduced 3.47%
13,900 $806,000
Q2 2023

Jul 07, 2023

SELL
$63.71 - $70.74 $6,562 - $7,286
-103 Reduced 0.71%
14,400 $920,000
Q4 2022

Jan 03, 2023

SELL
$68.48 - $81.09 $36,499 - $43,220
-533 Reduced 3.54%
14,503 $1.04 Million
Q3 2022

Oct 05, 2022

BUY
$0.13 - $76.84 $146 - $86,521
1,126 Added 8.09%
15,036 $1.07 Million
Q1 2022

Apr 13, 2022

BUY
$61.48 - $73.72 $71,931 - $86,252
1,170 Added 9.18%
13,910 $1.02 Million
Q3 2021

Oct 05, 2021

SELL
$59.17 - $69.31 $23,668 - $27,724
-400 Reduced 3.04%
12,740 $753,000
Q1 2021

Apr 06, 2021

BUY
$59.34 - $66.74 $59,340 - $66,740
1,000 Added 8.24%
13,140 $829,000
Q4 2020

Jan 11, 2021

BUY
$57.74 - $65.43 $5,947 - $6,739
103 Added 0.86%
12,140 $753,000
Q3 2019

Oct 04, 2019

SELL
$42.77 - $50.71 $4,277 - $5,071
-100 Reduced 0.82%
12,037 $610,000
Q4 2018

Jan 14, 2019

SELL
$48.76 - $63.23 $63,388 - $82,199
-1,300 Reduced 9.67%
12,137 $630,000
Q1 2018

Apr 16, 2018

SELL
$59.92 - $68.98 $8,988 - $10,347
-150 Reduced 1.1%
13,437 $0
Q3 2017

Oct 16, 2017

BUY
$55.23 - $63.74 $750,410 - $866,035
13,587
13,587 $0

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $121B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Lvm Capital Management LTD Portfolio

Follow Lvm Capital Management LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lvm Capital Management LTD, based on Form 13F filings with the SEC.

News

Stay updated on Lvm Capital Management LTD with notifications on news.